*Partial-onset seizures (focal) included simple partial seizures (focal motor seizure), complex partial seizures (focal impaired), and secondary generalized tonic-clonic seizures (focal to bilateral tonic-clonic).1,7


The only medication indicated to treat seizures associated with TSC, LGS, and Dravet syndrome in patients 1 year and older1

AED Icon

Structurally distinct from other AEDs1

Across 3 Indications Icon

Can be prescribed in adults and children as early as 1 year of age across 3 indications1

Bobby, age 41 | EPIDIOLEX patient living with Dravet syndrome

Bobby, age 41 | EPIDIOLEX patient living with Dravet syndrome

The first and only FDA-approved cannabidiol

Funnel Icon

Quality standards for stability and consistency1

Controlled Manufacturing Icon

Highly controlled manufacturing8

White Building Icon

No longer a federally scheduled drug1

Coverage Icon

Eligible for insurance coverage

Contaminant-free plants

Derived from pesticide- and contaminant-free plants8

Beaker Icon

Efficacy, safety, and dosing established across multiple controlled studies8

More patients like yours are discovering seizure reductions with EPIDIOLEX

Medal Icon

Within 1 year on market, EPIDIOLEX was prescribed to more than 15,000 patients by over 3000 prescribers in the United States—a number that only continues to grow9

People collaborating icon

EPIDIOLEX was studied in over 900 patients with LGS, Dravet syndrome, or TSC—making up the largest controlled clinical trial program for an AED in these conditions to date1,8,10,11†

There was a second randomized controlled trial in 199 patients with Dravet syndrome that has been completed since its original approval.10

Several EPIDIOLEX patients

Designed with your patients in mind, EPIDIOLEX offers flexible dosing for tolerability and response optimization1

See Flexible Dosing

Patient Collage Image